MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-29-2026
Pro-Dex Accounts Receivables 2011-2026 | PDEX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Pro-Dex
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.4 M | 13.9 M | 9.95 M | 15.4 M | 10.9 M | 5.16 M | 4.1 M | 2.96 M | 3.54 M | 1.47 M | 2.33 M | 1.78 M | 1.34 M | 1.58 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.4 M | 1.34 M | 6.49 M |
Quarterly Accounts Receivables Pro-Dex
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.9 M | 16.4 M | 15.9 M | 18.5 M | 13.5 M | 13.9 M | 12.5 M | 13.2 M | 11 M | 9.95 M | 10.6 M | 12.2 M | 11 M | 15.4 M | 8.68 M | 8.85 M | 10.1 M | 10.9 M | 10.9 M | 4.62 M | 6.14 M | 5.16 M | 5.16 M | 2.68 M | 3.16 M | 4.1 M | 4.1 M | 3.81 M | 3.62 M | 2.96 M | 2.96 M | 3.15 M | 2.25 M | 3.54 M | 3.54 M | 1.03 M | 1.54 M | 1.47 M | 1.47 M | 1.83 M | 759 K | 2.33 M | 2.33 M | 1.12 M | 1.09 M | 1.78 M | 1.78 M | 1.58 M | 1.36 M | 1.34 M | 1.34 M | 1.18 M | 1.84 M | 1.58 M | 1.58 M | 2.25 M | 2.33 M | 3.13 M | 3.13 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 M | 759 K | 5.82 M |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
829 M | $ 70.29 | 0.17 % | $ 14 B |  USA |
 |
Atrion Corporation
ATRI
|
23 K | - | - | $ 810 M | USA |
 |
Baxter International
BAX
|
1.7 B | $ 16.65 | -0.18 % | $ 8.54 B | USA |
 |
BioLife Solutions
BLFS
|
9.17 M | $ 19.27 | -1.23 % | $ 888 M | USA |
 |
AtriCure
ATRC
|
66.7 M | $ 29.19 | 0.41 % | $ 1.39 B | USA |
 |
electroCore
ECOR
|
1.03 M | $ 7.04 | 3.53 % | $ 59.7 K | USA |
 |
Ekso Bionics Holdings
EKSO
|
7.31 M | $ 9.75 | 3.72 % | $ 23.7 M | USA |
 |
Glaukos Corporation
GKOS
|
39.8 M | $ 116.69 | 3.48 % | $ 5.65 B | USA |
 |
Haemonetics Corporation
HAE
|
203 M | $ 58.46 | 2.87 % | $ 2.94 B | USA |
 |
Harvard Bioscience
HBIO
|
16 M | $ 5.53 | 6.35 % | $ 245 M | USA |
 |
ICU Medical
ICUI
|
181 M | $ 122.99 | -0.26 % | $ 3.03 B | USA |
 |
InfuSystem Holdings
INFU
|
16.9 M | $ 9.43 | 1.51 % | $ 195 M | USA |
 |
iRhythm Technologies
IRTC
|
75.7 M | $ 117.22 | 0.36 % | $ 3.75 B | USA |
 |
Isoray
ISR
|
6 K | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
1.53 B | $ 452.58 | 0.11 % | $ 162 B | USA |
 |
Repro Med Systems
KRMD
|
6.21 M | $ 4.26 | -1.39 % | $ 197 M | USA |
 |
LeMaitre Vascular
LMAT
|
33.6 M | $ 109.16 | 0.62 % | $ 2.47 B | USA |
 |
Masimo Corporation
MASI
|
141 M | $ 178.49 | -0.06 % | $ 9.51 B | USA |
 |
Microbot Medical
MBOT
|
159 K | $ 2.36 | -1.67 % | $ 108 M |  Israel |
 |
Milestone Scientific
MLSS
|
313 K | $ 0.29 | 1.9 % | $ 23.8 M | USA |
 |
Merit Medical Systems
MMSI
|
204 M | $ 67.81 | 0.16 % | $ 4.01 B | USA |
 |
Envista Holdings Corporation
NVST
|
430 M | $ 25.81 | - | $ 4.34 B | USA |
 |
Predictive Oncology
POAI
|
32.1 K | - | - | $ 31.1 M | USA |
 |
Pulse Biosciences
PLSE
|
274 K | $ 22.94 | -0.26 % | $ 1.55 B | USA |
 |
ResMed
RMD
|
576 M | $ 224.93 | 0.37 % | $ 32.9 B | USA |
 |
Retractable Technologies
RVP
|
7.9 M | $ 0.71 | 2.98 % | $ 21.3 M | USA |
 |
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
50.1 M | $ 20.96 | 3.71 % | $ 1.04 B | USA |
 |
STERIS plc
STE
|
1.04 B | $ 219.97 | 0.58 % | $ 21.7 B | USA |
 |
Stereotaxis
STXS
|
5.85 M | $ 1.88 | -0.53 % | $ 171 M | USA |
 |
Teleflex Incorporated
TFX
|
346 M | $ 115.04 | -2.35 % | $ 5.13 B | USA |
 |
Utah Medical Products
UTMD
|
3.52 M | $ 62.93 | -0.3 % | $ 204 M | USA |
 |
West Pharmaceutical Services
WST
|
574 M | $ 256.85 | 0.8 % | $ 18.6 B | USA |
 |
AngioDynamics
ANGO
|
42.9 M | $ 9.84 | -4.56 % | $ 402 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.99 B | $ 155.32 | 0.52 % | $ 44.7 B | USA |
 |
Nephros
NEPH
|
1.5 M | $ 2.86 | -0.35 % | $ 29.7 M | USA |
 |
OraSure Technologies
OSUR
|
22.2 M | $ 3.08 | - | $ 226 M | USA |
 |
Repligen Corporation
RGEN
|
124 M | $ 116.95 | -0.7 % | $ 6.52 M | USA |